{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:17:18Z","timestamp":1794712638881,"version":"4.9.1"},"reference-count":39,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T00:00:00Z","timestamp":1755820800000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Older patients who have acute myeloid leukemia (AML) with mutant TP53 and\/or complex karyotype have a dismal prognosis and lack treatment options. Having previously demonstrated that TP-0903, a multikinase inhibitor, has compelling preclinical activity in drug-resistant AML, including TP53-mutated AML, we evaluated the clinical activity of TP-0903 in combination with decitabine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This was a multicenter, open-label, phase 1b\/2 substudy of Beat AML Master Trial (ClinicalTrials.gov: NCT03013998). The phase 1b portion used a 3 + 3 design, and the phase 2 portion used a Simon two-stage design. Eligible patients ages \u226560 years who had newly diagnosed AML with mutations in TP53 and\/or complex karyotype (\u22653 cytogenetic abnormalities) received either 37 mg (group 1) or 25 mg (group 2) TP-0903 orally on days 1 to 21 with decitabine 20 mg\/m2 on days 1 to 10 for up to three 28-day induction cycles, followed by up to 30 maintenance cycles in which decitabine dosing was reduced to days 1 to 5. The primary endpoint was complete remission (CR) by the end of six cycles of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The overall composite remission rate (CR\/CR with incomplete count recovery\/CR with hematologic improvement) was 33.3% in group 1 and 50.0% in group 2, with CR rates of 13.3% and 25%, respectively. The median overall survival for groups 1 and 2 was 7.6 and 7.5 months, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The combination of TP-0903 and decitabine was reasonably tolerated and had activity in this patient population. Further research and novel treatment strategies are necessary to improve outcomes for patients with these high-risk subtypes of AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Treatment options for AML with mutant TP53 and\/or complex karyotype are limited. In a phase 1b\/2 clinical trial, TP-0903, a multikinase inhibitor, was well-tolerated and had activity comparable with other emerging therapies. Our results suggest that TP-0903 may offer insight and serve as a benchmark for the development of future agents leveraging similar strategies or scaffolds to improve outcomes in these intractable subtypes of AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0091","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T07:51:52Z","timestamp":1750837912000},"page":"1129-1139","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Phase 1b\/2 Study of TP-0903 and Decitabine Targeting Mutant\n                    <i>TP53<\/i>\n                    and\/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia \u2265Age 60 Years"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-675X","authenticated-orcid":false,"given":"Eric D.","family":"Eisenmann","sequence":"first","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3319-1870","authenticated-orcid":false,"given":"Ronan","family":"Swords","sequence":"additional","affiliation":[{"name":"2Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9910-1212","authenticated-orcid":false,"given":"Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-1409","authenticated-orcid":false,"given":"Shelley","family":"Orwick","sequence":"additional","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4413-5711","authenticated-orcid":false,"given":"Daelynn","family":"Buelow","sequence":"additional","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0316-2701","authenticated-orcid":false,"given":"Nicole","family":"Abbott","sequence":"additional","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1615-5280","authenticated-orcid":false,"given":"Mitch","family":"Phelps","sequence":"additional","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-1514","authenticated-orcid":false,"given":"Joshua","family":"Zeidner","sequence":"additional","affiliation":[{"name":"3University of North Carolina, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6652-3838","authenticated-orcid":false,"given":"Matthew C.","family":"Foster","sequence":"additional","affiliation":[{"name":"3University of North Carolina, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0242-6449","authenticated-orcid":false,"given":"Tara L.","family":"Lin","sequence":"additional","affiliation":[{"name":"4University of Kansas, Kansas City, Kansas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-1348","authenticated-orcid":false,"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[{"name":"5University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9573-2690","authenticated-orcid":false,"given":"Yazan F.","family":"Madanat","sequence":"additional","affiliation":[{"name":"6University of Texas Southwestern Medical Center, Dallas, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3294-0761","authenticated-orcid":false,"given":"Tibor","family":"Kovacsovics","sequence":"additional","affiliation":[{"name":"7The University of Utah, Salt Lake City, Utah."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2042-296X","authenticated-orcid":false,"given":"Robert","family":"Redner","sequence":"additional","affiliation":[{"name":"8University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8125-703X","authenticated-orcid":false,"given":"Zeina","family":"Al-Mansour","sequence":"additional","affiliation":[{"name":"9University of Florida, Gainesville, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4869-0712","authenticated-orcid":false,"given":"Bhavana","family":"Bhatnagar","sequence":"additional","affiliation":[{"name":"10West Virginia University Cancer Institute, Wheeling, West Virginia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3379-5794","authenticated-orcid":false,"given":"Mona","family":"Stefanos","sequence":"additional","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5596-079X","authenticated-orcid":false,"given":"Molly","family":"Martycz","sequence":"additional","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5281-1364","authenticated-orcid":false,"given":"Franchesca","family":"Druggan","sequence":"additional","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0932-5492","authenticated-orcid":false,"given":"Timothy L.","family":"Chen","sequence":"additional","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5353-1827","authenticated-orcid":false,"given":"Ashley O.","family":"Yocum","sequence":"additional","affiliation":[{"name":"11The Leukemia & Lymphoma Society, Rye Brook, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4958-4962","authenticated-orcid":false,"given":"Uma","family":"Borate","sequence":"additional","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8331-8206","authenticated-orcid":false,"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[{"name":"2Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9625-2813","authenticated-orcid":false,"given":"Amy","family":"Burd","sequence":"additional","affiliation":[{"name":"11The Leukemia & Lymphoma Society, Rye Brook, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7884-1905","authenticated-orcid":false,"given":"Ross L.","family":"Levine","sequence":"additional","affiliation":[{"name":"12Memorial Sloan Kettering Cancer Center, New York City, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8778-1000","authenticated-orcid":false,"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"13University of Cincinnati, Cincinnati, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3062-3252","authenticated-orcid":false,"given":"Sharyn D.","family":"Baker","sequence":"additional","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-2199","authenticated-orcid":false,"given":"Alice S.","family":"Mims","sequence":"additional","affiliation":[{"name":"1The Ohio State University, Columbus, Ohio."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"2025082211575002100_bib1","doi-asserted-by":"crossref","first-page":"e0278578","DOI":"10.1371\/journal.pone.0278578","article-title":"Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: a systematic review","volume":"17","author":"Hao","year":"2022","journal-title":"PLoS One"},{"key":"2025082211575002100_bib2","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","article-title":"Survival for older patients with acute myeloid leukemia: a population-based study","volume":"97","author":"Oran","year":"2012","journal-title":"Haematologica"},{"key":"2025082211575002100_bib3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"key":"2025082211575002100_bib4","first-page":"216","article-title":"Cytogenetic risk and hemocyte account for the age-related poor prognosis in adult acute myeloid leukemia patients","volume":"43","author":"Hu","year":"2021","journal-title":"Anal Quant Cytopatho"},{"key":"2025082211575002100_bib5","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","article-title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","volume":"26","author":"Burd","year":"2020","journal-title":"Nat Med"},{"key":"2025082211575002100_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.beha.2019.05.004","article-title":"Current status and new treatment approaches in TP53 mutated AML","volume":"32","author":"Hunter","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"key":"2025082211575002100_bib7","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2025082211575002100_bib8","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/leu.2008.143","article-title":"Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype","volume":"22","author":"Haferlach","year":"2008","journal-title":"Leukemia"},{"key":"2025082211575002100_bib9","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood"},{"key":"2025082211575002100_bib10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-021-01110-5","article-title":"A precision medicine classification for treatment of acute myeloid leukemia in older patients","volume":"14","author":"Mims","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2025082211575002100_bib11","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1182\/bloodadvances.2018023689","article-title":"Randomized trial of 10 days of decitabine \u00b1 bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)","volume":"2","author":"Roboz","year":"2018","journal-title":"Blood Adv"},{"key":"2025082211575002100_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2025082211575002100_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/14728214.2017.1330885","article-title":"Emerging cell cycle inhibitors for acute myeloid leukemia","volume":"22","author":"Abou Zahr","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"key":"2025082211575002100_bib14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4161\/cc.1.6.257","article-title":"Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function","volume":"1","author":"Dixon","year":"2002","journal-title":"Cell Cycle"},{"key":"2025082211575002100_bib15","doi-asserted-by":"crossref","first-page":"8998","DOI":"10.1158\/0008-5472.CAN-08-2658","article-title":"Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells","volume":"68","author":"Dar","year":"2008","journal-title":"Cancer Res"},{"key":"2025082211575002100_bib16","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3390\/molecules26071981","article-title":"Aurora kinase B inhibition: a potential therapeutic strategy for cancer","volume":"26","author":"Borah","year":"2021","journal-title":"Molecules"},{"key":"2025082211575002100_bib17","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1158\/0008-5472.CAN-08-0884","article-title":"Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells","volume":"68","author":"Gali-Muhtasib","year":"2008","journal-title":"Cancer Res"},{"key":"2025082211575002100_bib18","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1158\/1535-7163.MCT-13-0157","article-title":"Chk1\/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53","volume":"12","author":"Gadhikar","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"2025082211575002100_bib19","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1158\/1535-7163.MCT-17-0223","article-title":"Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer","volume":"16","author":"Alcaraz-Sanabria","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 7","key":"2025082211575002100_bib20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1158\/1538-7445.AM2023-392","article-title":"Abstract 392: targeting drug-resistant acute myeloid leukemia (AML) clone using casein kinase II inhibitor","volume":"83","author":"Mercer","year":"2023","journal-title":"Cancer Res"},{"key":"2025082211575002100_bib21","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood.2023021950","article-title":"PLK4, a potential target against AML","volume":"142","author":"Palm-Apergi","year":"2023","journal-title":"Blood"},{"key":"2025082211575002100_bib22","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/cncr.34780","article-title":"Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: a phase 2 substudy of the Beat AML Master Trial","volume":"129","author":"Duong","year":"2023","journal-title":"Cancer"},{"key":"2025082211575002100_bib23","doi-asserted-by":"crossref","first-page":"e140169","DOI":"10.1172\/jci.insight.140169","article-title":"TP-0903 is active in models of drug-resistant acute myeloid leukemia","volume":"5","author":"Jeon","year":"2020","journal-title":"JCI Insight"},{"key":"2025082211575002100_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/cancers15010029","article-title":"TP-0903 is active in preclinical models of acute myeloid leukemia with TP53 mutation\/deletion","volume":"15","author":"Eisenmann","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"Suppl 5","key":"2025082211575002100_bib25","doi-asserted-by":"crossref","first-page":"v172","DOI":"10.1093\/annonc\/mdz244.022","article-title":"A phase Ia\/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours","volume":"30","author":"Sarantopoulos","year":"2019","journal-title":"Ann Oncol"},{"key":"2025082211575002100_bib26","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"2025082211575002100_bib27","volume-title":"Common terminology criteria for adverse events (CTCAE). version 4.03","author":"NCI-CTEP","year":"2010"},{"key":"2025082211575002100_bib28","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1182\/bloodadvances.2022007952","article-title":"BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors","volume":"6","author":"Buelow","year":"2022","journal-title":"Blood Adv"},{"key":"2025082211575002100_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/OTT.S265637","article-title":"Targeting TP53-mutated acute myeloid leukemia: research and clinical developments","volume":"15","author":"Granowicz","year":"2022","journal-title":"Onco Targets Ther"},{"key":"2025082211575002100_bib30","doi-asserted-by":"crossref","first-page":"e0238795","DOI":"10.1371\/journal.pone.0238795","article-title":"Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine","volume":"15","author":"Bories","year":"2020","journal-title":"PLoS One"},{"key":"2025082211575002100_bib31","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"2025082211575002100_bib32","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/S2352-3026(22)00265-4","article-title":"Current status of phase 3 clinical trials in high-risk myelodysplastic syndromes: pitfalls and recommendations","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol"},{"key":"2025082211575002100_bib33","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025082211575002100_bib34","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025082211575002100_bib35","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe francophone des myelodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025082211575002100_bib36","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025082211575002100_bib37","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(22)00403-3","article-title":"Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study","volume":"10","author":"Garcia-Manero","year":"2023","journal-title":"Lancet Haematol"},{"key":"2025082211575002100_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2025082211575002100_bib39","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0091\/3626130\/crc-25-0091.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/7\/1129\/3631063\/crc-25-0091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/7\/1129\/3631063\/crc-25-0091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T15:58:03Z","timestamp":1755878283000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/7\/1129\/763559\/A-Phase-1b-2-Study-of-TP-0903-and-Decitabine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0091","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.29557190","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557211","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29968221","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557184","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29968215","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557241","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29968227","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29968203","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557208","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29968206","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29968218","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557226","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557238","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557202","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557214","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557193","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29968230","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29968197","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29968200","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557244","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557187","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29968212","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557220","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557232","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29968224","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29968209","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557217","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557229","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557205","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.29557235","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7926287","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}